Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma

The development of targeted therapies and immunotherapies has markedly advanced the treatment of metastasized melanoma. While treatment with selective BRAF(V600E) inhibitors (like vemurafenib or dabrafenib) leads to high response rates but short response duration, CTLA-4 blocking therapies induce su...

Descripción completa

Detalles Bibliográficos
Autores principales: Hooijkaas, Anna, Gadiot, Jules, Morrow, Michelle, Stewart, Ross, Schumacher, Ton, Blank, Christian U.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2012
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3429565/
https://www.ncbi.nlm.nih.gov/pubmed/22934253
http://dx.doi.org/10.4161/onci.20226

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3429565/
https://www.ncbi.nlm.nih.gov/pubmed/22934253
http://dx.doi.org/10.4161/onci.20226

Ejemplares similares